Stay updated with breaking news from Multiple Sclerosis Ms. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The use of the monoclonal antibody satralizumab for the long-term treatment of neuromyelitis optica spectrum disorder provides sustained freedom from relapse with no new safety concerns over 5 years.
Previous research has found that life stressors are linked to clinical MS flares.
Autologous stem cell transplant reduced the risk for relapses, compared with fingolimod and natalizumab, in a recent analysis.
Novel S1P1 receptor modulator cenerimod shows impact on disease activity in lupus, with more pronounced benefits in those with more severe disease.
Expanded labeling applies to MR condition leads, allowing for higher quality scan images for patients with chronic pain.